Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma

Next Previous
X
Search
Trial Profile

A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RATIONALE-208
  • Sponsors BeiGene

    • Most Recent Events

    • 20 Jul 2022 Status changed from active, no longer recruiting to completed.
    • 02 Jul 2022 Results of a sub-group analysis assessing number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab presented at the 24th World Congress on Gastrointestinal Cancer
    • 02 Jul 2022 Results (n=122) for Chinese subpopulation presented at the 24th World Congress on Gastrointestinal Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top